ALLMedicine™ Acromegaly Center
Research & Reviews 1,514 results
https://doi.org/10.1007/s11102-023-01307-6
Pituitary Khiyami A, Mehrotra N et. al.
Mar 18th, 2023 - Acromegaly is a disorder characterized by IGF-1 excess due to autonomous GH secretion. In individuals without acromegaly, IGF-1 is not only influenced by GH secretion but is also sensitive to other factors including nutritional status, as evidence...
https://doi.org/10.1007/s40618-023-02056-w
Journal of Endocrinological Investigation; Cianferotti L, Cipriani C et. al.
Mar 16th, 2023 - Bone is one of the main targets of hormones and endocrine diseases are frequent causes of secondary osteoporosis and fractures in real-world clinical practice. However, diagnosis of skeletal fragility and prediction of fractures in this setting co...
https://doi.org/10.1093/ejendo/lvad031
European Journal of Endocrinology; Falch CM, Christiansen Arlien-Søborg M et. al.
Mar 11th, 2023 - Active acromegaly is characterized by lipolysis-induced insulin resistance, which suggests adipose tissue (AT) as a primary driver of metabolic aberrations. To study the gene expression landscape in AT in patients with acromegaly before and after ...
https://doi.org/10.1007/s40618-022-01980-7
Journal of Endocrinological Investigation; Pirchio R, Auriemma RS et. al.
Mar 10th, 2023 - Pegvisomant (PEG) efficaciously controls IGF-I excess in acromegaly and possesses a positive impact on glucose metabolism. Data on very prolonged PEG treatment are still limited, therefore, we investigated the effects of 10-years PEG on disease co...
https://clinicaltrials.gov/ct2/show/NCT00001987
Mar 7th, 2023 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...
Guidelines 5 results
https://doi.org/10.1016/j.numecd.2016.02.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.
Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.
Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...
https://www.ncbi.nlm.nih.gov/pubmed/21846616
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.
Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...
https://www.ncbi.nlm.nih.gov/pubmed/19923883
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.
Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,
https://doi.org/10.1210/jc.2008-2421
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.
Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...
Drugs 31 results see all →
Clinicaltrials.gov 178 results
https://clinicaltrials.gov/ct2/show/NCT00001987
Mar 7th, 2023 - Study Description: Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistan...
https://clinicaltrials.gov/ct2/show/NCT04125836
Mar 6th, 2023 - The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to contin...
https://clinicaltrials.gov/ct2/show/NCT05752825
Mar 6th, 2023 - Patients with an established diagnosis of acromegaly will be recruited from March 2023 to March 2025. Patients will be informed of the study during scheduled visits to the pituitary endocrinology outpatient clinic at Aalborg University Hospital by...
https://clinicaltrials.gov/ct2/show/NCT05364944
Feb 28th, 2023 - This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreati...
https://clinicaltrials.gov/ct2/show/NCT05192382
Feb 9th, 2023 - A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromeg...
News 121 results
https://www.medpagetoday.com/neurology/generalneurology/101053
Oct 4th, 2022 - In super-agers -- people 80 and older with exceptional episodic memory -- entorhinal cortex neurons were significantly larger compared with cognitively average peers and individuals 20-30 years younger. (Journal of Neuroscience) A multimodal pain ...
https://www.medscape.com/viewarticle/977284
Jul 15th, 2022 - Men with type 2 diabetes are at higher risk for testosterone deficiency. And in turn, hypogonadism is commonly associated with metabolic syndrome or type 2 diabetes. However, this does not imply a specific need for action, as Stephan Petersenn, MD...
https://www.medpagetoday.com/endocrinology/generalendocrinology/98544
May 4th, 2022 - The FDA placed a clinical hold on Vertex's investigational diabetes cell therapy VX-880, saying the company didn't have enough evidence to support a treatment dose increase. (Fierce Biotech) A study from England found that surgeons who performed f...
https://www.medscape.com/viewarticle/969871
Mar 8th, 2022 - Dr Douglas S. Paauw A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin. Her stool toxin test is positive for Clostridio...
https://www.mdedge.com/internalmedicine/article/252401/infectious-diseases/practice-guidelines-highlights-past-year
Douglas S. Paauw, MD
Mar 3rd, 2022 - A 64-year-old woman is evaluated for fever, diarrhea, and abdominal pain. She was diagnosed with Clostridioides difficile 2 months ago and completed a 10-day course of vancomycin.